New Product Newswire
Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia
The drug is also approved to treat schizophrenia and bipolar depression.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
FDA Expands OA REMS, Mandates Mail-Back Envelopes for Opioid Analgesics
The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.
FDA Roundup: Agency Highlights from October 2024
Check out these important FDA updates from the month of October 2024.
FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain
The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.
FDA Approves Sulopenem Etzadroxil and Probenecid for Uncomplicated UTIs
The FDA has approved just the second treatment for uncomplicated urinary tract infections (UTIs) in the last 2 decades.